Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Avenacy Launched Norepinephrine Bitartrate Injection, USP in the U.S. Market

with severe, acute hypotension. Norepinephrine Bitartrate Injection, USP is available as a carton of ten 4 mg per 4 mL (1 mg per mL) single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care,...

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

maintaining familiar workflows with greater versatility by seamlessly switching between RF and PFA,” said Nicolas Derval1, M.D., Bordeaux, France. “This flexibility also provides greater ability to adjust treatment to different patient anatomies,...

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell...

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

lowering fasting triglyceride levels by up to 72% compared to placebo at six months and sustaining those reductions at 12 months. Additionally, TRYNGOLZA significantly reduced acute pancreatitis events by up to 91%. Among patients treated with...

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

lowering fasting triglyceride levels by up to 72% compared to placebo at six months and sustaining those reductions at 12 months. Additionally, TRYNGOLZA significantly reduced acute pancreatitis events by up to 91%. Among patients treated with...

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota. HOPE has installed Zeta TMS Navigation Systems at...

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

can visit: https://mykymbee.com/hcp. If you or your doctor have questions about KYMBEE™, reach out to Upsher-Smith at 1-888-650-3789. IMPORTANT SAFETY INFORMATION for KYMBEE™ (deflazacort) Who should not take KYMBEE? Do not take if you have had...

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Limited (PPL), (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal...

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen...

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years who have completed a primary pediatric...

Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Bortezomib for Injection in the United States. The product contains the same active ingredient as VELCADE®, as approved by...

WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

of the most prominent leaders in Italian and European biotech: founder of Gentium, a Nasdaq-listed company acquired in 2014 by Jazz Pharmaceuticals in a transaction worth approximately USD 1 billion, she is today President and co-founder of...

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

Rugiet, the performance medicine company that’s helped more than 500,000 men take control of their health, announced the expansion of its treatment areas to include longevity. Rugiet is bringing its physician-prescribed standards to an emerging...

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

is a next-generation mGBCA with a novel tetrameric structure and high relaxivity (a measure of signal enhancement).1 With this approval, AMBELVIST becomes the lowest-dose mGBCA in the U.S. AMBELVIST has a recommended dose of 0.01 mmol/kg actual...

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

inclusion economics due to its high purity. “Biovet's fermentation infrastructure serves customers across more than 100 countries. Bringing that capacity to EVERY's protein platform is a natural extension of what we do. We do not just scale...

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and...

DIA Global Annual Meeting

The DIA 2026 Global Annual Meeting is evolving, just like the life sciences community it serves. Join global innovators, regulators, academics, patient advocates, and industry leaders for an all-new experience designed to inspire, engage, and...

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL...

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

ELASTEN®, Germany's 1 liquid collagen supplement and a global leader in clinically studied ingestible skincare, announced a year-long partnership with renowned board-certified dermatologist, media expert, and trusted authority in cosmetic and...

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

HMOs with specific probiotic strains, including Bifidobacterium infantis Rosell®–33 and Bifidobacterium bifidum Rosell®-71, supplied by Lallemand. About NurtureBio NurtureBio is a maternal and child wellness company applying breakthrough breast...